[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100563192":3},{"organization":4,"outcomesModule":7,"designInfo":21,"detailedDescription":32,"studyPopulation":20,"armGroups":33,"interventions":64,"overallOfficials":77,"centralContacts":82,"locations":91,"responsibleParty":109,"collaborators":20,"id":111,"slug":20,"hasResults":112,"nctId":113,"briefTitle":114,"officialTitle":115,"acronym":20,"eligibilityCriteria":116,"healthyVolunteers":117,"sex":118,"minAge":119,"maxAge":120,"enrollmentInfo":121,"targetDuration":20,"studyType":124,"phases":125,"briefSummary":127,"conditions":128,"keywords":130,"overallStatus":93,"whyStopped":20,"lastUpdateSubmitDate":131,"lastUpdatePostDateStruct":132,"startDateStruct":135,"completionDateStruct":137,"leadSponsor":139,"locationsCount":140},{"fullName":5,"class":6},"Shanghai Huaota Biopharmaceutical Co., Ltd.","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":20},[9],{"measure":10,"description":11,"timeFrame":12},"Percentage of subjects with drug related adverse events (AEs)","An AE is any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of investigational drug","Up to 2700 hours",[14,17],{"measure":15,"description":16,"timeFrame":12},"Cmax","The maximum measured concentration of the analysis in plasma.",{"measure":18,"description":19,"timeFrame":12},"AUC0-infinity","The area under the concentration-time curve of the analysis in plasma over the time interval from 0 extrapolated to infinity",null,{"allocation":22,"interventionModel":23,"interventionModelDescription":20,"primaryPurpose":24,"observationalModel":20,"timePerspective":20,"maskingInfo":25},"RANDOMIZED","SEQUENTIAL","OTHER",{"masking":26,"maskingDescription":20,"whoMasked":27},"QUADRUPLE",[28,29,30,31],"PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR","This is a single-dose escalation study of HB0056 to evaluate the safety, tolerability, pharmacokinetics, and immunogenicity of HB0056.",[34,40,43,46,49,52,55,58],{"label":35,"type":36,"description":37,"interventionNames":38},"HB0056 dose group 1","ACTIVE_COMPARATOR","HB0056 single dose",[39],"Drug: HB0056",{"label":41,"type":36,"description":37,"interventionNames":42},"HB0056 dose group 2",[39],{"label":44,"type":36,"description":37,"interventionNames":45},"HB0056 dose group 3",[39],{"label":47,"type":36,"description":37,"interventionNames":48},"HB0056 dose group 4",[39],{"label":50,"type":36,"description":37,"interventionNames":51},"HB0056 dose group 5",[39],{"label":53,"type":36,"description":37,"interventionNames":54},"HB0056 dose group 6",[39],{"label":56,"type":36,"description":37,"interventionNames":57},"HB0056 dose group 7",[39],{"label":59,"type":60,"description":61,"interventionNames":62},"Matching placebo for each dose group","PLACEBO_COMPARATOR","placebo, single dose",[63],"Drug: Placebo",[65,72],{"type":66,"name":67,"description":68,"armGroupLabels":69,"otherNames":70},"DRUG","HB0056","HB0056 Injection",[35,41,44,47,50,53,56],[71],"Targeting TSLP and IL-11 IgG1-type Bispecific Antibody",{"type":66,"name":73,"description":73,"armGroupLabels":74,"otherNames":75},"Placebo",[59],[76],"No other invention name",[78],{"name":79,"affiliation":80,"role":81},"Cory Sellwood","New Zealand Clinical Research","PRINCIPAL_INVESTIGATOR",[83,88],{"name":84,"role":85,"phone":86,"phoneExt":20,"email":87},"Jingjing Wang","CONTACT","086 15002154126","jingjing.wang@huaota.com",{"name":89,"role":85,"phone":86,"phoneExt":20,"email":90},"Xiaoyan Liu","xiaoyan.liu@huaota.com",[92],{"facility":80,"status":93,"city":94,"state":20,"zip":95,"country":96,"countryCode":97,"cosmosGeoPoint":98,"geoPoint":103,"contacts":104},"RECRUITING","Christchurch","8011","New Zealand","NZ",{"type":99,"coordinates":100},"Point",[101,102],172.63333,-43.53333,{"lat":102,"lon":101},[105],{"name":106,"role":85,"phone":107,"phoneExt":20,"email":108},"Lucia Druzianic","+ 64 9 373 3474 ext. 7221","lucy.druzianic@nzcr.co.nz",{"type":110,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR","100563192",false,"NCT06612970","A Study to Evaluate Single-dose of HB0056 in Healthy Adult Participants","A Phase 1a, Randomized, Double-blind, Placebo-controlled, Single Dose-escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HB0056 in Adult Healthy Subjects.","Inclusion Criteria:\n\n* Healthy male or female subjects age ≥ 18 and ≤ 55 years.\n* Body Mass Index (BMI) ≥ 18 and ≤ 32 kg\u002Fm².\n* Normal ECG, blood pressure, respiratory rate, temperature, and heart rate, unless the investigator considers any abnormality to be not clinically significant.\n* Signed and dated written informed consent prior to admission to the study in accordance with GCP and local legislation.\n\nExclusion Criteria:\n\n* History of clinically significant cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, psychiatric, or neurological disease.\n* Current or history of malignancy. • Family history of premature Coronary Heart Disease (CHD)\n* History of clinically significant opportunistic infection (e.g., invasive candidiasis or pneumocystis pneumonia).\n* Pregnant or Breasting feeding subject. Women with a positive pregnancy test .\n* Further exclusions criteria applied.",true,"ALL","18 Years","55 Years",{"count":122,"type":123},46,"ESTIMATED","INTERVENTIONAL",[126],"PHASE1","The aim of this study is to investigate the safety and tolerability of HB0056 in healthy subjects following single-dose.",[129],"Healthy",[67],"2025-09-05",{"date":133,"type":134},"2025-09-08","ACTUAL",{"date":136,"type":134},"2024-11-18",{"date":138,"type":123},"2025-10-01",{"name":5,"class":6},1]